Avexisinc Now Known As Novartis Gene Therapiesis A Biotechnology Company Founded In 2010The Company Focuses On Developing Gene Therapies For Rare Neurological Genetic Disordersit Was Acquired By Novartis In 2018Which Enhanced Novartis S Commitment To Gene Therapy One Of The Key Products Developed By Novartis Gene Therapies Is Onasemnogene Abeparvovecmarketed As Zolgensmathis Gene Therapy Is Designed To Treat Spinal Muscular Atrophysma A Serious Genetic Disorder That Impacts Muscle Strength And Movementzolgensma Received Regulatory Approval In The United States In 2019 And Conditional Approval In The European Union In 2020The Company Operates Within The Biotechnology And Pharmaceutical Industriesutilizing Advanced Gene Therapy Technologies To Create Innovative Treatments For Genetic Diseases
